BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35883021)

  • 1. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids.
    Kooshki L; Zarneshan SN; Fakhri S; Moradi SZ; Echeverria J
    Phytomedicine; 2023 Apr; 112():154686. PubMed ID: 36804755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule drug discovery targeting the JAK-STAT pathway.
    Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
    Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.
    Roach CM; Bidne KL; Romoser MR; Ross JW; Baumgard LH; Keating AF
    J Anim Sci; 2022 Jul; 100(7):. PubMed ID: 35772766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen.
    Tai ZF; Zhang GL; Wang F
    Biol Pharm Bull; 2012; 35(1):65-71. PubMed ID: 22223339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
    Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
    Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
    Durham GA; Williams JJL; Nasim MT; Palmer TM
    Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer.
    Yunianto I; Currie M; Chitcholtan K; Sykes P
    J Obstet Gynaecol Res; 2023 Nov; 49(11):2563-2574. PubMed ID: 37565583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
    Liu J; Wang F; Luo F
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.